Skip to main content


Log in

Successful treatment of severe nodular scleritis with adalimumab

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript


Ocular features may occur in longstanding rheumatoid arthritis. Among them, scleritis represents the most frequent manifestation of ophthalmologic rheumatoid disease. There are three types of anterior scleritis: diffuse, nodular, and necrotizing with and without inflammation (scleromalacia perforans). Nodular scleritis is the second cause of anterior scleritis representing 20% of all types of scleritis. The conventional treatment of nodular scleritis consists in topical steroids and DMARDS. In severe cases, the therapy with immunosuppressive agents to avoid complications is necessary. We describe a 46-year-old woman presented right nodular scleritis with rheumatoid arthritis. She was treated initially with topical steroids and DMARDs but was unable to received systemic steroids due to left open angle glaucoma in the opposite eye. After an ocular exacerbation, we initiated adalimumab with complete resolution of nodular scleritis. This is the first report of adalimumab in the treatment of nodular scleritis. Adalimumab could be a good alternative in patients with severe nodular scleritis who fail to have conventional treatment with DMARDs and unable to receive systemic steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2


  1. Harper S, Foster C (1998) The ocular manifestations of rheumatoid disease. Int Ophthalmol Clin 38:1–19

    Article  CAS  PubMed  Google Scholar 

  2. McGavin D, Williamson J, Forrester J, Foulds W, Buchanan W, Dick W et al (1976) Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophtalmol 60:192–226

    Article  CAS  Google Scholar 

  3. Jabs D, Mudun A, Dunn J, Marsh M (2000) Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 130:469–476

    Article  CAS  PubMed  Google Scholar 

  4. Fuerst D, Tanzer D, Smith R (1998) Rheumatoid diseases. Int Ophthalmol Clin 38:47–80

    Article  CAS  PubMed  Google Scholar 

  5. Watson P, Hayreh S (1976) Scleritis and episcleritis. Br J Ophthalmol 60:163–191

    Article  CAS  PubMed  Google Scholar 

  6. Sen H, Sangare A, Hammel K, Levy-Clarke G, Nussenblatt R (2009) Infliximab for the treatment of active scleritis. Can J Ophtalmol 44:e9–e12

    Article  Google Scholar 

  7. Ashok D, Ayliffe W, Kiely P (2005) Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatol 44:950–951

    Article  CAS  Google Scholar 

  8. Ahn S, Oh J, Kim M, Wee W (2009) Treatment of refractory scleritis with infliximab. Jpn J Ophtalmol 53:286–287

    Article  Google Scholar 

  9. Chauhan S, Kamal A, Thompson R, Estrach C, Moots R (2009) Rituximab for the treatment associated with rheumatoid arthritis. Br J Ophtalmol 93:984–985

    Article  CAS  Google Scholar 

  10. Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh L et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411

    Article  CAS  PubMed  Google Scholar 

Download references



Author information

Authors and Affiliations


Corresponding author

Correspondence to Juan P. Restrepo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Restrepo, J.P., Molina, M.P. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 29, 559–561 (2010).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: